.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Long-term outcomes are especially important when comparing surgery with conservative treatment for slowly progressive cervical spondylotic myelopathy. A ten-year prospective randomized study followed patients with mild-to-moderate disease and compared operative and conservative strategies. At the final assessment, no major difference was found in modified JOA score, patient-rated outcome or observed daily activities between groups. The findings reinforce the importance of selecting the right population when interpreting evidence against surgery. Patients with mild and stable disease may not derive the same urgent benefit as patients with progressive neurological impairment. For HCPs, the practical lesson is to monitor trajectory carefully. Worsening gait, dexterity, weakness or objective myelopathy can change the treatment threshold even when symptoms initially appear mild. The paper also reminds clinicians that long-term functional outcomes can remain stable in some carefully selected patients managed without surgery. Shared decision-making should therefore incorporate neurological severity, rate of progression, imaging findings, patient preference and surgical risk rather than assuming that all cord compression requires immediate operative treatment.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Long-term outcomes are especially important when comparing surgery with conservative treatment for slowly progressive cervical spondylotic myelopathy. A ten-year prospective randomized study followed patients with mild-to-moderate disease and compared operative and conservative strategies. At the final assessment, no major difference was found in modified JOA score, patient-rated outcome or observed daily activities between groups. The findings reinforce the importance of selecting the right population when interpreting evidence against surgery. Patients with mild and stable disease may not derive the same urgent benefit as patients with progressive neurological impairment. For HCPs, the practical lesson is to monitor trajectory carefully. Worsening gait, dexterity, weakness or objective myelopathy can change the treatment threshold even when symptoms initially appear mild. The paper also reminds clinicians that long-term functional outcomes can remain stable in some carefully selected patients managed without surgery. Shared decision-making should therefore incorporate neurological severity, rate of progression, imaging findings, patient preference and surgical risk rather than assuming that all cord compression requires immediate operative treatment.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
